Learn More
—A single-chip dual-band tri-mode CMOS trans-ceiver that implements the RF and analog front-end for an IEEE 802.11a/b/g wireless LAN is described. The chip is implemented in a 0.25-m CMOS technology and occupies a total silicon area of 23 mm 2. The IC transmits 9 dBm/8 dBm error vector magnitude (EVM)-compliant output power for a 64-QAM OFDM signal. The(More)
OBJECTIVE To assess the efficacy and safety of golimumab over 104 weeks in patients with active ankylosing spondylitis. METHODS At baseline, patients with active ankylosing spondylitis (n=356) were randomly assigned (1:1.8:1.8) to subcutaneous injections of placebo (group 1), golimumab 50 mg (group 2) or golimumab 100 mg (group 3) every 4 weeks. At week(More)
OBJECTIVES To assess long-term golimumab efficacy/safety in patients with active psoriatic arthritis (PsA). METHODS Adult PsA patients (≥3 swollen, ≥3 tender joints, active psoriasis) were randomly assigned to subcutaneous injections of placebo, golimumab 50 mg or 100 mg every 4 weeks (q4wks) through week 20. All patients received golimumab 50 or 100 mg(More)
OBJECTIVE Identify serum biomarkers modulated by golimumab treatment and associated with clinical response in patients with ankylosing spondylitis (AS). METHODS Sera were collected at weeks 0, 4 and 14 from 100 patients with active AS in the GO-RAISE study. Patients were randomly assigned subcutaneous injections of placebo, golimumab 50 mg, or golimumab(More)
OBJECTIVE To evaluate the effect of golimumab on physical function, health-related quality of life (HRQOL), and productivity in psoriatic arthritis (PsA). METHODS GO-REVEAL was a multicenter, randomized, placebo-controlled study. Adult patients with active PsA (n = 405) received golimumab (50 or 100 mg) or placebo every 4 weeks, with early escape at week(More)
OBJECTIVE To assess pooled golimumab safety up to year 3 of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) trials. METHODS Golimumab 50 and 100 mg, administered subcutaneously (SC) every 4 weeks (q4wk), were assessed in patients with active RA (methotrexate-naïve, methotrexate-experienced and anti-TNF (tumour necrosis(More)
OBJECTIVE To determine serum biomarker associations with clinical response to golimumab treatment in patients with psoriatic arthritis (PsA). METHODS GO-REVEAL was a randomised, placebo-controlled study of golimumab in patients with active PsA. Samples were collected from 100 patients at baseline, week 4 and week 14, and analysed for serum-based(More)
— This paper describes a variation of a kernel-level Intrusion Detection System (IDS). In particular, it is real time so it could be described as an intrusion prevention system. In addition to looking at system calls as others have done, we also look at arguments to system calls as well as Process IDs (PIDs) and parent PIDs. Also, we focus on the "(More)